Gout
Conditions
Interventions
1:4 weeks of low-dose colchicine for preventing
2:12 weeks of low-dose colchicine for preventing
3:24 weeks of low-dose colchicine for preventing
Sponsors
The Second Affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Aged 18 to 75 years old male or female; 2) Meet the diagnostic criteria for primary gout; 3) Acute flare within 1 month, without urate lowering therapy, serum uric acid >420umol/L.
Exclusion criteria
Exclusion criteria: 1) Those who are allergic to all the drugs or ingredients in this test, or those who are allergic to the disease, or those with high sensitivity; 2) Azorazin, 6-mercaptopurine, cyclosporine, cyclophosphamide, pyrazinamide, sulfamethoxazole, trimethoprim, theophylline, warfarin or other coumarins are currently or need a drug such as a coagulant; 3) patients with active peptic ulcer, malignant tumors, and active tuberculosis; 4) Arthritis caused by other causes has been diagnosed; 5) heart failure, unstable heart pain, history of myocardial infarction or other serious heart disease in the past 12 months; 6) Patients with secondary hyperuricemia caused by blood diseases, malignant tumors, kidney diseases or tumor radiotherapy and chemotherapy; 7) Patients with active liver disease or cirrhosis, or abnormal liver function (serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) exceeds the upper limit of the normal range by 2.5 times; 8) white blood cell count <4.0 × 10^9/L, or platelets <100×10^9/L, or hemoglobin <90g/l; 9) Brain diseases, abnormal judgment ability, and mental disorders cannot cooperate; 10) History of alcohol abuse or illegal drugs; 11) Pregnant women, pregnant or lactating women; 12) For any other reason, the investigator believes that it is inappropriate to participate in the tester.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| total times of flare; | — |
Secondary
| Measure | Time frame |
|---|---|
| flare times in 4/12/24 weeks;target serum uric acid level achievement rate;tophus volume change in tophaeous gout;vas score of flares,peak time,duration;dosage of NSAIDs of prednisone;rate of abnormal liver function; | — |
Countries
China
Contacts
Public ContactWu Huaxiang
The Second Affiliated Hospital, Zhejiang University School of Medicine
Outcome results
None listed